Add Rainbow Children's Medicare Ltd For Target Rs.1,650 by Choice Institutional Equities Ltd
A Multi-year Expansion Story with Earnings Visibility:
RAINBOW is entering into a multi-year growth phase, supported by a ~1,200-bed expansion pipeline, improving occupancy across new hospitals, strengthening specialty and fertility services and selective acquisitions. Backed by a debt-free balance sheet and strong cash generation, the management expects ~20% annual growth with sustained margin expansion and long-term value-creation.
View and Valuation: We maintain Revenue/EBITDA/APAT to expand at a CAGR of 20.6%/21.8%/28.0% over FY26–FY29E. Valuing the stock at an EV/EBITDA multiple of 22x (maintained) on FY28E, we maintain our target price to INR 1,650 and change our rating to an ‘ADD’ (from BUY), due to recent stock performance.
Record capacity-addition creates multi-year growth runway:
RAINBOW is entering a strong growth phase with nearly 1,200 beds currently under development. Mainly across Andhra Pradesh (~150 beds), Gurugram (~450 beds), Coimbatore (~130 beds), Bengaluru (80 beds), while also making its entry into Indore (~75 beds), Pune (~150 beds), Mumbai (~100 beds) hospital. These facilities are expected to be commissioned over the next 2.5–3 years. Despite this aggressive expansion, RAINBOW continues to deliver one of the highest profitability profiles in healthcare sector. The upcoming hospitals are expected to progressively improve occupancy, margin and return ratios as they mature, supporting management's target of sustaining ~20% annual revenue growth. This combination of robust capacity expansion, superior profitability and a visible earnings runway positions RAINBOW for a compelling long-term value-creation.
Multiple growth engines position RAINBOW for sustainable ~20% growth: RAINBOW delivered ~33% revenue growth in Q1FY27, driven by strong 28% growth in inpatient discharges, 25% increase in outpatient volumes and 23% growth in deliveries, demonstrating broad-based demand across both mature and new hospitals. Management has guided for ~20% growth in the coming year, supported by multiple structural drivers. These include occupancy improvement across recently-commissioned hospitals, expansion of highvalue specialty care, fertility business expected to grow ~25% annually over the next 3 years, increasing transplant volumes, digital initiatives to improve patient conversion and selective acquisitions in attractive micro-markets. With Bengaluru, Chennai and other regional hubs still maturing, RAINBOW expects a stronger service mix, higher asset utilisation and expanding clinical capabilities to drive sustainable revenue and earnings growth over the medium term.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
